Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.51%
#2 Fake World Assets Fake World Assets +18.28%
#3 Status Status +17.90%
#4 GoPlus Security GoPlus Security +11.51%
#5 Ontology Gas Ontology Gas +10.01%
#6 Bedrock Bedrock +7.70%
#7 DMT-NAT DMT-NAT +7.61%
#8 Cap Cap +6.73%
#9 Provenance Blockchain Provenance Blockchain +6.73%
#10 Janction Janction +5.45%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Renalytix Plc Renalytix Plc

Renalytix Plc

RNLX
Kedudukan dalam Saham #33998
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc... Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.
Harga Saham
$0.1502
Disegerakkan terakhir: 2024-11-04
Modal Pasaran
$6.43M
Perubahan (1 hari)
-5.45%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Renalytix Plc (RNLX)

Kategori

Healthcare
Nisbah P/E bagi Renalytix Plc (RNLX)
Nisbah P/E pada August 2026 TTM: -0.33
Menurut laporan kewangan dan harga saham terkini Renalytix Plc, nisbah P/E semasa (TTM) ialah -0.33. Pada akhir 2023, syarikat mempunyai nisbah P/E sebanyak -2.63.
Sejarah nisbah P/E bagi Renalytix Plc dari 2018 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) -0.33 -18.54%
2024 -0.41 -84.59%
2023 -2.63 43.09%
2022 -1.84 -94.16%
2021 -31.49 -20.69%
2020 -39.71 484.63%
2019 -6.79 -96.98%
2018 -225.00 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
GE HealthCare Technologies Inc. GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc.
GEHC.US
 21.18 -6,439.91%
US
Pro Medicus Limited Pro Medicus Limited
Pro Medicus Limited
PME.AX
 79.49 -23,900.39%
AU
BrightSpring Health Services, Inc. Common Stock BrightSpring Health Services, Inc. Common Stock
BrightSpring Health Services, Inc. Common Stock
BTSG.US
 43.15 -13,020.30%
US
Tempus AI, Inc. Tempus AI, Inc.
Tempus AI, Inc.
TEM.US
 -36.43 10,808.26%
US
Signify Health, Inc. Signify Health, Inc.
Signify Health, Inc.
SGFY.US
 - -
US
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.